6 results
The primary objective of this trial is to describe the safety and tolerability of prolonged exposure to cebranopadol in subjects suffering from cancer related pain
Comparison of steady-state cysteamine-trough WBC cystine levels between Cystagon® and RP103 over 3 months for each treatment period.
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
Primary objective:To assess the two-year prevalence and incidence of clinical relevant arrhythmias in drug-resistant epilepsy.Secondary objective:To assess whether the recorded cardiac arrhythmias are related to epileptic seizures (subjectively from…
- To assess the pharmacokinetic profile of cysteamine base after single dose administration of the new sustained-release cysteamine bitartrate (PO-001) to healthy volunteers, in comparison with Cystagon® and Procysbi®.- To collect safety/…
Primary • To evaluate the effects of cebranopadol and oxycodone on respiratory drive.Secondary• To evaluate the pupil response/ pupillometry following single oral doses of cebranopadol and oxycodone• To evaluate the effects of single oral doses of…